BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

226 related articles for article (PubMed ID: 23151902)

  • 1. Histone deacetylase inhibitor AR-42 differentially affects cell-cycle transit in meningeal and meningioma cells, potently inhibiting NF2-deficient meningioma growth.
    Burns SS; Akhmametyeva EM; Oblinger JL; Bush ML; Huang J; Senner V; Chen CS; Jacob A; Welling DB; Chang LS
    Cancer Res; 2013 Jan; 73(2):792-803. PubMed ID: 23151902
    [TBL] [Abstract][Full Text] [Related]  

  • 2. AR42, a novel histone deacetylase inhibitor, as a potential therapy for vestibular schwannomas and meningiomas.
    Bush ML; Oblinger J; Brendel V; Santarelli G; Huang J; Akhmametyeva EM; Burns SS; Wheeler J; Davis J; Yates CW; Chaudhury AR; Kulp S; Chen CS; Chang LS; Welling DB; Jacob A
    Neuro Oncol; 2011 Sep; 13(9):983-99. PubMed ID: 21778190
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Natural compounds as potential treatments of NF2-deficient schwannoma and meningioma: cucurbitacin D and goyazensolide.
    Spear SA; Burns SS; Oblinger JL; Ren Y; Pan L; Kinghorn AD; Welling DB; Chang LS
    Otol Neurotol; 2013 Oct; 34(8):1519-27. PubMed ID: 23928514
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overexpression of eIF4F components in meningiomas and suppression of meningioma cell growth by inhibiting translation initiation.
    Oblinger JL; Burns SS; Huang J; Pan L; Ren Y; Shen R; Kinghorn AD; Welling DB; Chang LS
    Exp Neurol; 2018 Jan; 299(Pt B):299-307. PubMed ID: 28610844
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Group I Paks as therapeutic targets in NF2-deficient meningioma.
    Chow HY; Dong B; Duron SG; Campbell DA; Ong CC; Hoeflich KP; Chang LS; Welling DB; Yang ZJ; Chernoff J
    Oncotarget; 2015 Feb; 6(4):1981-94. PubMed ID: 25596744
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Loss of PTPRJ/DEP-1 enhances NF2/Merlin-dependent meningioma development.
    Waldt N; Scharnetzki D; Kesseler C; Kirches E; Stroscher N; Böhmer FD; Mawrin C
    J Neurol Sci; 2020 Jan; 408():116553. PubMed ID: 31715329
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Natural history of meningioma development in mice reveals: a synergy of Nf2 and p16(Ink4a) mutations.
    Kalamarides M; Stemmer-Rachamimov AO; Takahashi M; Han ZY; Chareyre F; Niwa-Kawakita M; Black PM; Carroll RS; Giovannini M
    Brain Pathol; 2008 Jan; 18(1):62-70. PubMed ID: 17924978
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Modeling NF2 with human arachnoidal and meningioma cell culture systems: NF2 silencing reflects the benign character of tumor growth.
    James MF; Lelke JM; Maccollin M; Plotkin SR; Stemmer-Rachamimov AO; Ramesh V; Gusella JF
    Neurobiol Dis; 2008 Feb; 29(2):278-92. PubMed ID: 17962031
    [TBL] [Abstract][Full Text] [Related]  

  • 9. First insight into the somatic mutation burden of neurofibromatosis type 2-associated grade I and grade II meningiomas: a case report comprehensive genomic study of two cranial meningiomas with vastly different clinical presentation.
    Dewan R; Pemov A; Dutra AS; Pak ED; Edwards NA; Ray-Chaudhury A; Hansen NF; Chandrasekharappa SC; Mullikin JC; Asthagiri AR; ; Heiss JD; Stewart DR; Germanwala AV
    BMC Cancer; 2017 Feb; 17(1):127. PubMed ID: 28193203
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Generation of Noninvasive, Quantifiable, Orthotopic Animal Models for NF2-Associated Schwannoma and Meningioma.
    Burns SS; Chang LS
    Methods Mol Biol; 2016; 1427():59-72. PubMed ID: 27259921
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neurofibromatosis Type 2 (NF2) and the Implications for Vestibular Schwannoma and Meningioma Pathogenesis.
    Bachir S; Shah S; Shapiro S; Koehler A; Mahammedi A; Samy RN; Zuccarello M; Schorry E; Sengupta S
    Int J Mol Sci; 2021 Jan; 22(2):. PubMed ID: 33445724
    [TBL] [Abstract][Full Text] [Related]  

  • 12. EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma.
    Angus SP; Oblinger JL; Stuhlmiller TJ; DeSouza PA; Beauchamp RL; Witt L; Chen X; Jordan JT; Gilbert TSK; Stemmer-Rachamimov A; Gusella JF; Plotkin SR; Haggarty SJ; Chang LS; Johnson GL; Ramesh V;
    Neuro Oncol; 2018 Aug; 20(9):1185-1196. PubMed ID: 29982664
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Alterations of INK4a(p16-p14ARF)/INK4b(p15) expression and telomerase activation in meningioma progression.
    Simon M; Park TW; Köster G; Mahlberg R; Hackenbroch M; Boström J; Löning T; Schramm J
    J Neurooncol; 2001 Dec; 55(3):149-58. PubMed ID: 11859969
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Validation of a scoring system to evaluate the risk of rapid growth of intracranial meningiomas in neurofibromatosis type 2 patients.
    Abi Jaoude S; Peyre M; Degos V; Goutagny S; Parfait B; Kalamarides M
    J Neurosurg; 2020 May; 134(5):1377-1385. PubMed ID: 32442973
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Inhibition of NF2-negative and NF2-positive primary human meningioma cell proliferation by overexpression of merlin due to vector-mediated gene transfer.
    Ikeda K; Saeki Y; Gonzalez-Agosti C; Ramesh V; Chiocca EA
    J Neurosurg; 1999 Jul; 91(1):85-92. PubMed ID: 10389885
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The role and regulatory mechanism of IL-1β on the methylation of the NF2 gene in benign meningiomas and leptomeninges.
    Wang B; Cui Z; Zhong Z; Sun Y; Yang GY; Sun Q; Bian L
    Mol Carcinog; 2016 Dec; 55(12):2268-2277. PubMed ID: 26840621
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A high-throughput kinome screen reveals serum/glucocorticoid-regulated kinase 1 as a therapeutic target for NF2-deficient meningiomas.
    Beauchamp RL; James MF; DeSouza PA; Wagh V; Zhao WN; Jordan JT; Stemmer-Rachamimov A; Plotkin SR; Gusella JF; Haggarty SJ; Ramesh V
    Oncotarget; 2015 Jul; 6(19):16981-97. PubMed ID: 26219339
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Animal models of meningiomas.
    Mawrin C
    Chin Clin Oncol; 2017 Jul; 6(Suppl 1):S6. PubMed ID: 28595424
    [TBL] [Abstract][Full Text] [Related]  

  • 19. NF2 Gene Participates in Regulation of the Cell Cycle of Meningiomas by Restoring Spindle Assembly Checkpoint Function and Inhibiting the Binding of Cdc20 Protein to Anaphase Promoting Complex/Cyclosome.
    Ma M; Ge Y; Zhang T
    World Neurosurg; 2022 Feb; 158():e245-e255. PubMed ID: 34728400
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways.
    Chen YJ; Wang WH; Wu WY; Hsu CC; Wei LR; Wang SF; Hsu YW; Liaw CC; Tsai WC
    PLoS One; 2017; 12(8):e0183368. PubMed ID: 28829799
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.